Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19
Oral C21 treatment demonstrates significant clinical improvement on top of corticosteroids Gothenburg, December 08, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today announces positive top line data from the ATTRACT COVID-19 trial with C21 (VP01). A webcast presentation will be held today at 15:00 CET (9 am EST).The ATTRACT study was a randomized, double-blind and placebo-controlled trial investigating the efficacy of oral C21 compared with placebo in 106 hospitalized COVID-19 patients with signs